Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE study of early calcineurin inhibitor to everolimus conversion after kidney transplantation
NL-OMON34407Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, tacrolimus and cyclosporine in kidney transplant (2 arms), sponsored by Novartis. Primary endpoint: Renal allograft function at month 12. Started Sep 2010; status: active, not recruiting.
02
Drugs
everolimustacrolimuscyclosporine
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON34407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34407.